A client needed to move into clinic as soon as possible. By evaluating a matrix of potential excipients for compatibility with the active and in vitro release, IriSys created a lipid based dosage form for a highly insoluble active, and improved bioavailability from 5% to 90%.  IriSys’ formulation enabled client to enter the clinic, satisfy investors, obtain additional financing and soon thereafter, file an Initial Public Offering.  The drug product went into Phase III in the form of a tablet.  If the tablet dosage form, requiring significantly more time, had been pursued initially, essential data would have been delayed substantially, from 1 to 2 years, and as a result, investors may have responded less aggressively.

This entry was posted on Thursday, April 2nd, 2009 at 2:14 pm and is filed under Uncategorized. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.